During platinum/paclitaxel-based neo-adjuvant treatment for high grade serous ovarian cancer, an intron 4 donor splice mutation (c.375 + 1G > A) became the highly proliferative major clone, suggesting that this TP53 mutation was potentially associated with chemotherapy resistance [33]. This evidence concerns the gene TP53 and ovarian serous adenocarcinoma.